Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting

Phase 1

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Sponsor:

Therapeutic Advances in Childhood Leukemia Consortium

Code:

NCT05476770

Conditions

Hematologic Malignancy

AML

ALL

BPDCN

MDS

Eligibility Criteria

Sex: All

Age: 1 - 21

Healthy Volunteers: Not accepted

Interventions

Tagraxofusp

Fludarabine

Cytarabine

Dexamethasone

Vincristine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-02. This information was provided to ClinicalTrials.gov by Therapeutic Advances in Childhood Leukemia Consortium on 2024-12-06.